Jazz Pharmaceuticals (JAZZ) Revenue (2010 - 2026)
Jazz Pharmaceuticals' quarterly Revenue came in at $1.1 billion in Q1 2026, up 19.06% year-on-year from $897.8 million in Q1 2025, and down 10.77% quarter-over-quarter from $1.2 billion in Q4 2025.
Jazz Pharmaceuticals has reported Revenue for 17 years, with the latest figure at $1.1 billion in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 19.06% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (up 9.2% YoY), and the FY2025 full-year result was $4.3 billion, up 4.88% from the prior year.
- Revenue for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
- The five-year high for Revenue was $1.2 billion in Q4 2025, with the low at $813.7 million in Q1 2022.
- Average Revenue over 5 years is $994.1 million, with a median of $972.1 million recorded in 2023.
- Year-over-year, Revenue jumped 33.93% in 2022 and decreased 0.46% in 2025.
- Tracing JAZZ's Revenue over 5 years: stood at $972.1 million in 2022, then grew by 4.1% to $1.0 billion in 2023, then increased by 7.53% to $1.1 billion in 2024, then climbed by 10.09% to $1.2 billion in 2025, then retreated by 10.77% to $1.1 billion in 2026.
- The last three Revenue figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 1.20 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 1.05 Bn |
| Mar 31, 2025 | 897.80 Mn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.02 Bn |
| Mar 31, 2024 | 901.98 Mn |
| Dec 31, 2023 | 1.01 Bn |
| Sep 30, 2023 | 972.14 Mn |
| Jun 30, 2023 | 957.32 Mn |
| Mar 31, 2023 | 892.81 Mn |
| Dec 31, 2022 | 972.12 Mn |
| Sep 30, 2022 | 940.65 Mn |
| Jun 30, 2022 | 932.88 Mn |
| Mar 31, 2022 | 813.72 Mn |
| Dec 31, 2021 | 896.73 Mn |
| Sep 30, 2021 | 838.12 Mn |
| Jun 30, 2021 | 751.81 Mn |
| Mar 31, 2021 | 607.58 Mn |
| Dec 31, 2020 | 665.52 Mn |
| Sep 30, 2020 | 600.89 Mn |
| Jun 30, 2020 | 562.44 Mn |
| Mar 31, 2020 | 534.73 Mn |
| Dec 31, 2019 | 581.74 Mn |
| Sep 30, 2019 | 537.70 Mn |
| Jun 30, 2019 | 534.13 Mn |
| Mar 31, 2019 | 508.19 Mn |
| Dec 31, 2018 | 476.46 Mn |
| Sep 30, 2018 | 469.37 Mn |
| Jun 30, 2018 | 500.48 Mn |
| Mar 31, 2018 | 444.61 Mn |
| Dec 31, 2017 | 436.40 Mn |
| Sep 30, 2017 | 411.86 Mn |
| Jun 30, 2017 | 394.39 Mn |
| Mar 31, 2017 | 376.05 Mn |
| Dec 31, 2016 | 396.62 Mn |
| Sep 30, 2016 | 374.18 Mn |
| Jun 30, 2016 | 381.16 Mn |
| Mar 31, 2016 | 336.01 Mn |
| Dec 31, 2015 | 340.88 Mn |
| Sep 30, 2015 | 340.87 Mn |
| Jun 30, 2015 | 333.75 Mn |
| Mar 31, 2015 | 309.30 Mn |
| Dec 31, 2014 | 328.14 Mn |
| Sep 30, 2014 | 306.58 Mn |
| Jun 30, 2014 | 291.23 Mn |
| Mar 31, 2014 | 246.92 Mn |
| Dec 31, 2013 | 235.77 Mn |
| Sep 30, 2013 | 232.16 Mn |
| Jun 30, 2013 | 208.25 Mn |
| Mar 31, 2013 | 196.24 Mn |
| Dec 31, 2012 | 183.70 Mn |
| Sep 30, 2012 | 175.52 Mn |
| Jun 30, 2012 | 124.23 Mn |
| Mar 31, 2012 | 102.53 Mn |
| Dec 31, 2011 | 83.54 Mn |
| Sep 30, 2011 | 72.22 Mn |
| Jun 30, 2011 | 63.46 Mn |
| Mar 31, 2011 | 50.88 Mn |
| Dec 31, 2010 | 83.54 Mn |
| Sep 30, 2010 | 73.29 Mn |
| Jun 30, 2010 | 64.57 Mn |